Outcomes in Patients with Psoriasis Following Apremilast Treatment: Results from the German Psoriasis Registry PsoBest
Patients in routine care treated with apremilast in the German PsoBest registry experienced treatment benefits and improved skin, psoriasis severity, and quality of life. Safety was consistent with the established safety profile. Apremilast is safe and effective for treating moderate to severe psoriatic disease.
Authors
- Myriam Cordey (ORCID: https://orcid.org/0009-0004-1797-0510)
- Kathy Tran
- Stephan Jeff Rustenbach
- Hamid Amouzadeh
- Ulrich Mrowietz
- Matthias Augustin
- Ralph von Kiedrowski
Institutions
- Amgen (United States) (US)
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Clinical Research Center Kiel (DE)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1007/s13555-025-01631-8
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Celgene